These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 31445768)

  • 61. Initial experience with sentinel node biopsy in breast cancer at the National Cancer Center Hospital East.
    Imoto S; Hasebe T
    Jpn J Clin Oncol; 1999 Jan; 29(1):11-5. PubMed ID: 10073145
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Imaging-Based Approach to Axillary Lymph Node Staging and Sentinel Lymph Node Biopsy in Patients With Breast Cancer.
    Sun SX; Moseley TW; Kuerer HM; Yang WT
    AJR Am J Roentgenol; 2020 Feb; 214(2):249-258. PubMed ID: 31714846
    [No Abstract]   [Full Text] [Related]  

  • 63. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Independent risk factors for axillary lymph node metastasis in breast cancer patients with one or two positive sentinel lymph nodes.
    Zhang W; Xu J; Wang K; Tang XJ; Liang H; He JJ
    BMC Womens Health; 2020 Jul; 20(1):143. PubMed ID: 32646416
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Experience of sentinel node biopsy alone in early breast cancer without further axillary dissection in patients with negative sentinel node.
    Soni NK; Spillane AJ
    ANZ J Surg; 2005 May; 75(5):292-9. PubMed ID: 15932439
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure.
    Derkx F; Maaskant-Braat AJ; van der Sangen MJ; Nieuwenhuijzen GA; van de Poll-Franse LV; Roumen RM; Voogd AC
    Eur J Surg Oncol; 2010 Jul; 36(7):646-51. PubMed ID: 20537838
    [TBL] [Abstract][Full Text] [Related]  

  • 68. De-escalation of axillary surgery in patients outside Z0011 criteria.
    Giannakou A; Gooch J; Gergelis KR; Weiss A
    Surgery; 2023 Aug; 174(2):416-418. PubMed ID: 37156648
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer.
    Gooch J; King TA; Eaton A; Dengel L; Stempel M; Corben AD; Morrow M
    Ann Surg Oncol; 2014 Sep; 21(9):2897-903. PubMed ID: 24777858
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
    Zetterlund LH; Frisell J; Zouzos A; Axelsson R; Hatschek T; de Boniface J; Celebioglu F
    Breast Cancer Res Treat; 2017 May; 163(1):103-110. PubMed ID: 28224384
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quality of life after sentinel lymph node biopsy versus complete axillary lymph node dissection in early breast cancer: a 3-year follow-up study.
    Boguševičius A; Čepulienė D
    Medicina (Kaunas); 2013; 49(3):111-7. PubMed ID: 23893054
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
    Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
    Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of sentinel lymph node biopsy prior to axillary lymph node dissection: the role of isolated tumor cells/micrometastases and multifocality/multicentricity-a retrospective study of 1214 breast cancer patients.
    Schröder L; Fricker R; Stein RG; Rink T; Fitz H; Blasius S; Wöckel A; Müller T
    Arch Gynecol Obstet; 2018 Jun; 297(6):1509-1515. PubMed ID: 29594495
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice.
    Lee SB; Yu JH; Park H; Kim HJ; Park SH; Chae BJ; Youn HJ; Jung SY; Kim EK; Jung YS; Son BH
    Asian J Surg; 2019 Jan; 42(1):314-319. PubMed ID: 30049563
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 78. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
    de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Axillary dissection in sentinel lymph node positive breast cancer: Is the staging information worthwhile for patients?
    Chang DW; Bressel M; Hansen C; Blinman P; Schofield P; Chua BH
    Asia Pac J Clin Oncol; 2021 Apr; 17(2):e27-e34. PubMed ID: 31461222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.